ADC Therapeutics targets $600M–$1B in peak ZYNLONTA revenue amid expansion into DLBCL market
Discover key insights from ADC Therapeutics' Q4 2024 earnings call, including ZYNLONTA’s commercial success, clinical trial updates, and strategic ...
Zacks Investment Research on MSN15h
ADC Therapeutics SA (ADCT) Reports Q4 Loss, Misses Revenue Estimates
ADC Therapeutics SA (ADCT) came out with a quarterly loss of $0.29 per share versus the Zacks Consensus Estimate of a loss of $0.35. This compares to loss of $1.03 per share a year ago. These figures ...